Candid Therapeutics, a new biotech company, secured over $370 million in funding to develop treatments for autoimmune diseases. The funding will allow them to operate for several years and explore opportunities for an initial public offering.

Clinical stage biotechnology company dedicated to advancing the treatment of a range of immunological conditions





www.candidrx.com

Therapeutics

Candid Therapeutics raised $370M in a Series A funding round to develop antibody drugs for inflammatory diseases.

Description

Company Information

Related People

Funding Insights

Candid Therapeutics raised $370M in a Series A funding round to develop antibody drugs for inflammatory diseases.

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Related People

Funding Insights

Company Information